Figure 5.
psCV1-hIgG1 ex vivo transfected tumor cells show significantly reduced growth in vivo
(A and B) CD47 expression in a 231/LM2-4-EGFPLuc lymph node metastasis 34 days after orthotopic implantation with (A) huCD47 staining and (B) isotype control staining; 4× magnification images with zoomed-in 40× magnification images. Scale bars: 200 μm (4× magnification) and 20 μm (40× magnification. (C–G) 231/LM2-4-EGFPLuc were transfected ex vivo with the indicated plasmid and 48 h thereafter orthotopically implanted into the 4th pair of inguinal nipples (2 sites/animal) in female CB17-SCID mice. Two experiments [Exp I (C and E) and Exp II (D, F, G)] were conducted. Exp I was terminated 34 days after implantation and Exp II after 25 days. 3 animals/group were used, and the BLI signal at each injection site was quantified within a separate ROI (i.e., n = 6 +SD per group). (C and D) Tumor growth followed by BLI. (E and F) Size of explanted tumors after termination. (G) Representative BLI pictures (color coded, overlaid onto a reflected light picture) of animals in Exp II 18 days after implantation. (C and D): n = 6 per experiment, ∗∗p ≤ 0.01, ∗p ≤ 0.05; psCV1-hIgG1 transfected versus pmCherry transfected; U test (Mann-Whitney). Scale bars in E and F: 2 cm.